Effect of memantine in Alzheimer's disease evaluated by visual-evoked potentials to pattern-reversal, motion-onset, and cognitive stimuli

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F10%3A10081326" target="_blank" >RIV/00216208:11150/10:10081326 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00179906:_____/10:10081326

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Effect of memantine in Alzheimer's disease evaluated by visual-evoked potentials to pattern-reversal, motion-onset, and cognitive stimuli

Popis výsledku v původním jazyce

Visual evoked potentials (VEPs) to pattern-reversal and motion stimulation as well as visual cognitive potentials (ERPs) were examined in 17 patients with mild to moderate Alzheimer disease before onset of Memantin treatment and after 3 and 6 months of Memantine therapy. The electrophysiological tests were able to prove a significant beneficial effect of Memantine therapy in our group of patients. Improvement of ERPs (shortening of P300 peak latency by at least 20 ms) occurred in 42% of patients. On theother hand, Memantine therapy led in 52% of patients to transitory decline of motion processing (delay of N2 peak latency of the motion-onset VEPs by at least 10 ms after the first 3 months of therapy, followed by return to pre-therapy values in next 3months).

Název v anglickém jazyce

Effect of memantine in Alzheimer's disease evaluated by visual-evoked potentials to pattern-reversal, motion-onset, and cognitive stimuli

Popis výsledku anglicky

Visual evoked potentials (VEPs) to pattern-reversal and motion stimulation as well as visual cognitive potentials (ERPs) were examined in 17 patients with mild to moderate Alzheimer disease before onset of Memantin treatment and after 3 and 6 months of Memantine therapy. The electrophysiological tests were able to prove a significant beneficial effect of Memantine therapy in our group of patients. Improvement of ERPs (shortening of P300 peak latency by at least 20 ms) occurred in 42% of patients. On theother hand, Memantine therapy led in 52% of patients to transitory decline of motion processing (delay of N2 peak latency of the motion-onset VEPs by at least 10 ms after the first 3 months of therapy, followed by return to pre-therapy values in next 3months).

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2010

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Clinical Neurophysiology

ISSN

0736-0258

e-ISSN

—

Svazek periodika

27

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

7

Strana od-do

—

Kód UT WoS článku

000282362400005

EID výsledku v databázi Scopus

—